Published

Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Journal of psychopharmacology (Oxford, England)
Date: 2024-03-01
Source: PubMed
DOI: 10.1177/02698811231225609
PubMed: 38214279

Authors

Rouaud A Calder AE Hasler G

Watch author

Derived topics and classifications

psilocybin Receptor Pharmacology Microdosing Review Article Safety Review Article

Citation graph

0 referenced DOIs found in stored source metadata. 5 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. Adults2026-10-01 Cardiovascular safety of psilocybin in psychiatric practice: a narrative review2026-08-01 Psilocybin and Mental Health Outcomes: Scoping Review with ☸️SAIMSARA2026-06-15 Psilocybin microdosing in the United States: Insights from a nationally representative survey2026-03-08 Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins.2024-03-01

Related papers

No close related records were found yet.